Lilly's Strategic Advancements in CLL/SLL and Myelofibrosis Markets

Lilly's Strategic Advancements in CLL/SLL and Myelofibrosis Markets | Eli Lilly Intelligence | Humanexa

Evidence Sources

Source-backed references used to construct this page.

Hepatitis C Medicines (Mavyret, Zepatier, and Vosevi): Drug Safety Communication - Due to Rare Occurrence of Serious Liver Injury in Some patients with Advanced Liver Disease
FDA
FDA document
View source
MHRA review of the benefits and risks of avacopan
MHRA
FDA document
View source
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1
ClinicalTrials.gov
FDA document
View source
LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.
ClinicalTrials.gov
FDA document
View source
Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy
ClinicalTrials.gov
FDA document
View source
CAPRA-EVO: Randomized Serial PCCT Trial of Early Evolocumab After ACS
ClinicalTrials.gov
FDA document
View source
Neurophysiology of Reward Signaling in Parkinson's Disease
ClinicalTrials.gov
FDA document
View source
RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMed
FDA document
View source
Wrist-Ankle Acupuncture on Postoperative Nausea and Vomiting Prophylaxis in High-Risk Female Patients: A Pragmatic, Randomized, Single-Blind, Sham-Controlled Trial.
PubMed
FDA document
View source
Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial.
PubMed
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMed
FDA document
View source
Increasing plant protein sources in the diet modulates gut microbiota and tryptophan metabolism in men at cardiometabolic risk.
PubMed
FDA document
View source
Lilly's Jaypirca shows 45% reduction in disease progression risk in CLL/SLL
Lilly
FDA document
View source
Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
Lilly Investor Relations
FDA document
View source
Lilly presents promising Phase 1 data for first-in-class type II JAK2 inhibitor in myelofibrosis
Lilly
FDA document
View source
Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting
Eli Lilly
FDA document
View source
Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
FDA
FDA document
View source
FDA AP — EMGALITY (SUPPL)
FDA
FDA document
View source
FDA AP — EBGLYSS (SUPPL)
FDA
FDA document
View source
FDA AP — EMGALITY (SUPPL)
FDA
FDA document
View source

Lilly's Strategic Advancements in CLL/SLL and Myelofibrosis Markets

Asset Overview

Company Context

Regulatory Timeline

Lilly presents promising Phase 1 data for first-in-class type II JAK2 inhibitor in myelofibrosis

FDA AP — EMGALITY (SUPPL)

FDA AP — EBGLYSS (SUPPL)

FDA AP — EMGALITY (SUPPL)

Clinical trials for medicines: modifying a clinical trial approval

Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death

Lilly's Jaypirca shows 45% reduction in disease progression risk in CLL/SLL

Related Signals

Evidence Sources